AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34129271 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 48
Study 33499197 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling kuromoji tea aroma
Number of subjects: 0
Study 33499197 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking kuromoji tea
Number of subjects: 0
Study 36400737 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Connections (CC) intervention, a peer-based, recurrent letter writing programme designed to provide moments of positivity.
Number of subjects: 0
Study 36400737 — intervention group
Group type: COMPARATOR
Intervention: Attention control group receiving informational materials on life domains important to a good quality of life.
Number of subjects: 0
Study 36400737 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Connections (CC) intervention
Number of subjects: 0
Study 35743631 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Rehabilitation Program (ICRP) for 10 weeks
Number of subjects: 40
Study 35743631 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 33243182 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week customised vestibular rehabilitation (VR) programme consisting of 12 face-to-face sessions and a home exercise programme.
Number of subjects: 100
Study 33243182 — intervention group
Group type: COMPARATOR
Intervention: 12-week generic booklet-based home programme with telephone support.
Number of subjects: 100
Study 33243182 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised VR intervention.
Number of subjects: 100
Study 33243182 — intervention group
Group type: COMPARATOR
Intervention: Generic booklet-based intervention.
Number of subjects: 100
Study 34311382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued stop-signal task with varying stop-signal probabilities (0%, 25%, 66%)
Number of subjects: 0
Study 34311382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued stop-signal task
Number of subjects: 0
Study 32154734 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum educational leaflet
Number of subjects: 3534
Study 32154734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 3534
Study 34557931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranger Drug‐Coated Balloon (DCB)
Number of subjects: 102
Study 34557931 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous transluminal angioplasty (PTA)
Number of subjects: 102
Study 33731199 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanglaite injections (KLTi) 200 ml per day for 14 days
Number of subjects: 334
Study 33731199 — intervention group
Group type: COMPARATOR
Intervention: First-line platinum-based double chemotherapy regimens
Number of subjects: 334
Study 35942041 — intervention group
Group type: EXPERIMENTAL
Intervention: JET + PCB
Number of subjects: 47
Study 35942041 — intervention group
Group type: COMPARATOR
Intervention: PTA + PCB
Number of subjects: 47
Study 33518358 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention (Quit and Fit)
Number of subjects: 38
Study 33518358 — intervention group
Group type: COMPARATOR
Intervention: Control group (smoking cessation counseling and nicotine lozenges)
Number of subjects: 38
Study 33518358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis for intervention group
Number of subjects: 38
Study 33518358 — intervention group
Group type: COMPARATOR
Intervention: Intent-to-treat analysis for control group
Number of subjects: 38
Study 34995105 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib with adjuvant endocrine therapy (ET) for 2 years
Number of subjects: 5743
Study 34995105 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant endocrine therapy (ET) alone
Number of subjects: 5743
Study 34717099 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional (3D) visualisation intervention (n = 20)
Number of subjects: 38
Study 34717099 — intervention group
Group type: COMPARATOR
Intervention: Traditional education control group (n = 18)
Number of subjects: 38
Study 32647965 — intervention group
Group type: EXPERIMENTAL
Intervention: B85E15
Number of subjects: 5
Study 32647965 — intervention group
Group type: EXPERIMENTAL
Intervention: B100
Number of subjects: 5
Study 32647965 — intervention group
Group type: EXPERIMENTAL
Intervention: B85G15
Number of subjects: 5
Study 32647965 — intervention group
Group type: COMPARATOR
Intervention: B85G15 and B100
Number of subjects: 5
Study 36308260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritive pacifiers (NPs)
Number of subjects: 100
Study 36308260 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive pacifiers (NNPs)
Number of subjects: 100
Study 36308260 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 33065273 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation and electrical dry needling
Number of subjects: 142
Study 33065273 — intervention group
Group type: COMPARATOR
Intervention: Spinal mobilization and exercise
Number of subjects: 142
Study 34098201 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) phone counseling calls
Number of subjects: 382
Study 34098201 — intervention group
Group type: COMPARATOR
Intervention: Prenatal and postpartum care as usual (Control)
Number of subjects: 382
Study 34114720 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4822
Study 34114720 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4822
Study 35427470 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis plus synthesised 2D mammography
Number of subjects: 99869
Study 35427470 — intervention group
Group type: COMPARATOR
Intervention: Digital mammography
Number of subjects: 99869
Study 32216724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill flowable resin composites
Number of subjects: 11
Study 32216724 — intervention group
Group type: COMPARATOR
Intervention: Conventional flowable resin composites
Number of subjects: 11
Study 33676840 — intervention group
Group type: EXPERIMENTAL
Intervention: Mel4 antimicrobial peptide‐coated contact lenses (MACL)
Number of subjects: 176
Study 33676840 — intervention group
Group type: COMPARATOR
Intervention: Uncoated control lenses
Number of subjects: 176
Study 34680134 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular iodine (I2) supplementation (5 mg/day)
Number of subjects: 0
Study 34680134 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with molecular iodine (Cht+I2)
Number of subjects: 0
Study 35277146 — intervention group
Group type: COMPARATOR
Intervention: Standardized training module
Number of subjects: 120
Study 35277146 — intervention group
Group type: COMPARATOR
Intervention: Hygiene kit
Number of subjects: 120
Study 35277146 — intervention group
Group type: COMPARATOR
Intervention: Training module and hygiene kit
Number of subjects: 120
Study 35277146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 32783051 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal AF (PxAF)
Number of subjects: 212
Study 32783051 — intervention group
Group type: EXPERIMENTAL
Intervention: 99-100% AF burden
Number of subjects: 212
Study 34954044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib combination (tucatinib + trastuzumab + capecitabine)
Number of subjects: 612
Study 34954044 — intervention group
Group type: COMPARATOR
Intervention: Placebo combination (placebo + trastuzumab + capecitabine)
Number of subjects: 612
Study 34780528 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Project (BP) intervention
Number of subjects: 90
Study 34780528 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight Program (HW) intervention
Number of subjects: 90
Study 34780528 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 90
Study 33205906 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy
Number of subjects: 253
Study 33205906 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 253
Study 33205906 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate plus etanercept)
Number of subjects: 253
Study 33205906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue therapy (combination regimen)
Number of subjects: 253
Study 32019823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Number of subjects: 21
Study 32019823 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic synthesis of hand hygiene interventions
Number of subjects: 21
Study 34913147 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Dynamic Scalp Acupuncture (IDSA)
Number of subjects: 231
Study 34913147 — intervention group
Group type: COMPARATOR
Intervention: Simple Combination Therapy (SCT)
Number of subjects: 231
Study 34913147 — intervention group
Group type: COMPARATOR
Intervention: Traditional Scalp Acupuncture (TSA)
Number of subjects: 231
Study 32241205 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched cosmetic product (ECP)
Number of subjects: 40
Study 32241205 — intervention group
Group type: COMPARATOR
Intervention: Placebo cosmetic product (PCP)
Number of subjects: 40
Study 35099437 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based team training in a simulated environment
Number of subjects: 32
Study 35099437 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures and hands-on pelvic models
Number of subjects: 32
Study 35285902 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-positive group (TPG)
Number of subjects: 1032
Study 35285902 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-negative group (TNG)
Number of subjects: 1032
Study 35285902 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1032
Study 33992169 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold compliance tool
Number of subjects: 54
Study 33325186 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hr2Dx method for processing and diagnosing prostate biopsies
Number of subjects: 44
Study 33325186 — intervention group
Group type: COMPARATOR
Intervention: Routine, slide-based 2D histology
Number of subjects: 44
Study 34550375 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-for-gestational age (SGA; <10th percentile)
Number of subjects: 735
Study 34550375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW; <2500 g)
Number of subjects: 735
Study 34550375 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth (<37 weeks of gestation)
Number of subjects: 735
Study 33884713 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO), 25 mL/day for 52 days
Number of subjects: 62
Study 33884713 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil, 25 mL/day for 52 days
Number of subjects: 62
Study 32464532 — intervention group
Group type: EXPERIMENTAL
Intervention: GC-rs4588-A minor allele
Number of subjects: 239
Study 32464532 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR-rs7975232-A
Number of subjects: 239
Study 32464532 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy Malaysian children)
Number of subjects: 239
Study 34767896 — intervention group
Group type: EXPERIMENTAL
Intervention: PIZ > median (>14 ml)
Number of subjects: 704
Study 34767896 — intervention group
Group type: EXPERIMENTAL
Intervention: PIZ volume in patients with MACE
Number of subjects: 704
Study 34767896 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of PIZ to CMR risk model
Number of subjects: 704
Study 34767896 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis In Myocardial Infarction (TIMI) risk score
Number of subjects: 704
Study 34736452 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Mothers and Babies Course & Early Childhood Development (iMBC/ECD)
Number of subjects: 374
Study 34736452 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in social support
Number of subjects: 374
Study 34736452 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in couple communication
Number of subjects: 374
Study 32057574 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Dose (SD) - 2 standard doses on weeks 0 and 4
Number of subjects: 87
Study 32057574 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Dose (DD) - 2 double-standard doses on weeks 0 and 4
Number of subjects: 87
Study 32057574 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster Dose (BD) - 3 standard doses on weeks 0, 4, and 12
Number of subjects: 87
Study 32057574 — intervention group
Group type: COMPARATOR
Intervention: Control group (SD and DD)
Number of subjects: 87
Study 34767030 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC) injection
Number of subjects: 60
Study 34767030 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 60
Study 33358336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg kg−1 h−1) with propofol infusion
Number of subjects: 349
Study 33358336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%) with propofol infusion
Number of subjects: 349
Study 35688582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen-Sleeve procedure
Number of subjects: 88
Study 35688582 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 88
Study 32935997 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-targeted treatments
Number of subjects: 0
Study 32935997 — intervention group
Group type: COMPARATOR
Intervention: Control arm patients
Number of subjects: 0
Study 32966982 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (BoNT‐A)
Number of subjects: 30
Study 33892048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar eye drops
Number of subjects: 68
Study 33892048 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (placebo)
Number of subjects: 68
Study 35946123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Cetylpyridinium Chloride (CPC) mouthwash
Number of subjects: 219
Study 35946123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine Gluconate (CHX) mouthwash
Number of subjects: 219
Study 35946123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 34689304 — intervention group
Group type: EXPERIMENTAL
Intervention: New galenics nasal spray (nasic® neo)
Number of subjects: 0
Study 34689304 — intervention group
Group type: COMPARATOR
Intervention: Comparator nasal spray
Number of subjects: 0
Study 34689304 — intervention group
Group type: EXPERIMENTAL
Intervention: New galenics nasal spray (nasic® neo) in subgroup with pronounced inflammation
Number of subjects: 0
Study 32907366 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986141 (400 ng/mL)
Number of subjects: 15
Study 32907366 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-968141 (combined with low-dose apixaban)
Number of subjects: 15
Study 32907366 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (low-dose 20 ng/mL)
Number of subjects: 15
Study 32907366 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986141 (combined with apixaban)
Number of subjects: 15
Study 36415003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task (DT) training for three weekly sessions for 8 weeks, 60 min each
Number of subjects: 30
Study 36415003 — intervention group
Group type: COMPARATOR
Intervention: Activities of daily living
Number of subjects: 30
Study 32751196 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D plasma levels
Number of subjects: 0
Study 32751196 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk levels of 25(OH)D
Number of subjects: 0
Study 32751196 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant plasma levels
Number of subjects: 0
Study 32751196 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between mother and infant plasma levels
Number of subjects: 0
Study 36183051 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-Cognitive Behavioral Therapy for Suicidal Behaviors (SCBT-SB)
Number of subjects: 46
Study 36183051 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 46
Study 33269798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovac EV71 vaccine (Older-S group)
Number of subjects: 600
Study 33269798 — intervention group
Group type: COMPARATOR
Intervention: Control EV71 vaccine (Older-C group)
Number of subjects: 600
Study 33269798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovac EV71 vaccine (Younger-S group)
Number of subjects: 600
Study 32381420 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus pemetrexed/carboplatin
Number of subjects: 0
Study 32381420 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab, pemetrexed/carboplatin, and bevacizumab
Number of subjects: 0
Study 33129962 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline catheter-based IV strategy
Number of subjects: 120
Study 32449542 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation (STN-DBS)
Number of subjects: 36
Study 32449542 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation off/medication on condition
Number of subjects: 36
Study 32449542 — intervention group
Group type: COMPARATOR
Intervention: Stimulation off
Number of subjects: 36
Study 33360684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lys-FFA (500 mg EPA plus 302 mg DHA)
Number of subjects: 8
Study 33360684 — intervention group
Group type: COMPARATOR
Intervention: EE (504 mg EPA plus 378 mg DHA)
Number of subjects: 8
Study 34807806 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-directed feedback
Number of subjects: 40
Study 34807806 — intervention group
Group type: COMPARATOR
Intervention: Self-assessment using video
Number of subjects: 40
Study 35940567 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC placebo plus HCQ
Number of subjects: 926
Study 34469796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematoporphyrin derivative
Number of subjects: 25
Study 34469796 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine digluconate
Number of subjects: 25
Study 34469796 — intervention group
Group type: COMPARATOR
Intervention: Sodium perborate enzyme
Number of subjects: 25
Study 34469796 — intervention group
Group type: COMPARATOR
Intervention: Citric acid
Number of subjects: 25
Study 33905630 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Reveal app (used for 12 weeks) in Subgroup C (fixed insulin dose)
Number of subjects: 75
Study 33905630 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Reveal app (used for 12 weeks) in Subgroup B (carbohydrate counting)
Number of subjects: 75
Study 33905630 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A, treated with continuous subcutaneous insulin infusion (CSII))
Number of subjects: 75
Study 33386821 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (WBC), 20 sessions
Number of subjects: 114
Study 33386821 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 33078435 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily aerobic cycling exercise (35 min at 60% VO2max)
Number of subjects: 31
Study 33078435 — intervention group
Group type: COMPARATOR
Intervention: Control group (stretching routine)
Number of subjects: 31
Study 33078435 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study 32503602 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (0.1 ml of the licensed BCG vaccine, Danish strain 1331, SSI, Denmark, equivalent to 0.075 mg attenuated M. bovis)
Number of subjects: 3100
Study 32503602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1 ml 0.9% NaCl)
Number of subjects: 3100
Study 33588784 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign language learning (Spanish course for beginners)
Number of subjects: 60
Study 33588784 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 60
Study 35349884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with Frenkel Coordination Exercises, 3 sessions per week for 6 weeks
Number of subjects: 32
Study 35349884 — intervention group
Group type: COMPARATOR
Intervention: Frenkel Coordination Exercise training (Control Group)
Number of subjects: 32
Study 33752964 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with at least one ED visit
Number of subjects: 101
Study 33752964 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with incident ED visits
Number of subjects: 101
Study 36084065 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional IVES
Number of subjects: 76
Study 36084065 — intervention group
Group type: COMPARATOR
Intervention: IVES with an open circuit
Number of subjects: 76
Study 35372857 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF
Number of subjects: 24
Study 35372857 — intervention group
Group type: COMPARATOR
Intervention: HD
Number of subjects: 24
Study 35038432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab plus platinum-based chemotherapy (1200 mg intravenously every 3 weeks)
Number of subjects: 479
Study 35038432 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy
Number of subjects: 479
Study 35038432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab plus chemotherapy
Number of subjects: 479
Study 35038432 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 479
Study 35038432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab
Number of subjects: 479
Study 35038432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study 33373011 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-endoscopic technique
Number of subjects: 80
Study 33373011 — intervention group
Group type: COMPARATOR
Intervention: 2D-endoscopic technique
Number of subjects: 80
Study 33373011 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 2D vs 3D
Number of subjects: 80
Study 36498288 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy using PNF, NDT-Bobath methods and the SPIDER system
Number of subjects: 120
Study 36498288 — intervention group
Group type: COMPARATOR
Intervention: Therapy using PNF and NDT-Bobath methods, without the SPIDER system
Number of subjects: 120